Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Concepts in Pharmacogenomics and Personalized Medicine
31
141. Rieder, M.J., et al. Effect of VKORC1 haplotypes on transcriptional regulation and
warfarin dose. N Engl J Med, 2005; 352(22): 2285–93.
142. Gage, B.F., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic
dose of warfarin. Clin Pharmacol Ther, 2008; 84(3): 326–31.
143. McClain, M.R., et al. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to
inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious
bleeding. Genet Med, 2008; 10(2): 89–98.
144. Klein, T.E., et al. Estimation of the warfarin dose with clinical and pharmacogenetic
data. N Engl J Med, 2009; 360(8): 753–64.
145. Pirmohamed, M., et al. A randomized trial of genotype-guided dosing of warfarin.
N Engl J Med, 2013; 369(24): 2294–303.
146. Aithal, G.P., et al. Association of polymorphisms in the cytochrome P450 CYP2C9
with warfarin dose requirement and risk of bleeding complications. Lancet, 1999;
353(9154): 717–19.
147. Taube, J., D. Halsall, and T. Baglin. Influence of cytochrome P-450 CYP2C9 polymorphisms
on warfarin sensitivity and risk of over-anticoagulation in patients on long-term
treatment. Blood, 2000; 96(5): 1816–19.
148. Eckman, M.H., et al. Cost-effectiveness of using pharmacogenetic information in warfarin
dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med, 2009;
150(2): 73–83.
149. National Coalition for Health Professional Education in Genetics. Core Competencies
for All Health Care Professionals. 2007. Available from: http://www.nchpeg.org/index.​
php?option=com_content&view=article&id=237&Itemid=84 (accessed March 12, 2014).
150. Johnson, J.A., et al. Pharmacogenomics: A scientific revolution in pharmaceutical sciences
and pharmacy practice. Report of the 2001–2002 Academic Affairs Committee.
Am J Pharm Educ, 2002; 66(Winter Suppl): 12S–15S.
151. Burke, J.M., et al. Clinical pharmacist competencies. Pharmacotherapy, 2008; 28(6):
806–15.
152. Ferro, W.G., et al. Pharmacist education in the era of genomic medicine. J Am Pharm
Assoc (2003), 2012; 52(5): e113–21.
153. American Academy of Family Physicians (AAFP) Core Educational Guidelines. Am
Fam Physician, 1999; 60(1): 305–7.
154. Ikediobi, O.N., et al. Addressing the challenges of the clinical application of pharmacogenetic
testing. Clin Pharmacol Ther, 2009; 86(1): 28–31.
155. Calzone, K.A., et al. Establishing the outcome indicators for the essential nursing
competencies and curricula guidelines for genetics and genomics. J Prof Nurs, 2011;
27(3): 179–91.
156. Johnson, S.W. and S. Henderson. Genetics of warfarin sensitivity in an emergency
department population with thromboembolic. West J Emerg Med, 2011; 12(1): 11–16.
157. Kuo, G.M., et al. Institutional Profile: University of California San Diego
Pharmacogenomics Education Program (PharmGenEd): Bridging the gap between science
and practice. Pharmacogenomics, 2011; 12(2): 149–53.
158. Latif, D.A. Pharmacogenetics and pharmacogenomics instruction in schools of pharmacy
in the USA: Is it adequate? Pharmacogenomics, 2005; 6(4): 317–19.
159. Murphy, J.E., et al. Pharmacogenomics in the curricula of colleges and schools of pharmacy
in the United States. Am J Pharm Educ, 2010; 74(1): 7.
160. Green, J.S., et al. Pharmacogenomics instruction in US and Canadian medical schools:
Implications for personalized medicine. Pharmacogenomics, 2010; 11(9): 1331–40.
161. Prows, C., K. Calzon, and J. Jenkins. Genetics content in nursing curriculum. Proceedings
of the National Coalition for Health Professional Education in Genetics, 2006.
162. Calzone, K.A. and J. Jenkins. Genomics education in nursing in the United States.
Annu Rev Nurs Res, 2011; 29: 151–72.